Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% ...

52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...

In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...

TDA's Canine Decontamination Kit is exclusively available from Mantel Technologies. This kit provides a safe and effective means of decontaminating dogs exposed to toxic substances. TDA Research ...